Immix Biopharma (NASDAQ:IMMX – Get Free Report) and Athira Pharma (NASDAQ:ATHA – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, risk, earnings, profitability, valuation, dividends and institutional ownership.
Valuation & Earnings
This table compares Immix Biopharma and Athira Pharma”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Immix Biopharma | N/A | N/A | -$21.61 million | ($0.77) | -7.56 |
| Athira Pharma | N/A | N/A | -$96.94 million | ($9.68) | -0.75 |
Risk & Volatility
Immix Biopharma has a beta of 0.33, indicating that its stock price is 67% less volatile than the S&P 500. Comparatively, Athira Pharma has a beta of 2.95, indicating that its stock price is 195% more volatile than the S&P 500.
Profitability
This table compares Immix Biopharma and Athira Pharma’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Immix Biopharma | N/A | -263.56% | -119.99% |
| Athira Pharma | N/A | -107.06% | -89.89% |
Analyst Ratings
This is a summary of current ratings and target prices for Immix Biopharma and Athira Pharma, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Immix Biopharma | 1 | 1 | 1 | 0 | 2.00 |
| Athira Pharma | 1 | 0 | 0 | 0 | 1.00 |
Immix Biopharma presently has a consensus price target of $8.00, indicating a potential upside of 37.36%. Athira Pharma has a consensus price target of $4.00, indicating a potential downside of 45.13%. Given Immix Biopharma’s stronger consensus rating and higher probable upside, equities analysts plainly believe Immix Biopharma is more favorable than Athira Pharma.
Institutional and Insider Ownership
11.3% of Immix Biopharma shares are held by institutional investors. Comparatively, 57.1% of Athira Pharma shares are held by institutional investors. 55.4% of Immix Biopharma shares are held by company insiders. Comparatively, 22.1% of Athira Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Summary
Immix Biopharma beats Athira Pharma on 6 of the 11 factors compared between the two stocks.
About Immix Biopharma
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.
About Athira Pharma
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies. The company's product pipeline includes ATH-1020, an orally available brain-penetrant small molecule designed to enhance the HGF/MET system that is in Phase 1 clinical trials to treat neuropathic pain and neurodegenerative diseases; and ATH-1105, an oral small molecule drug candidate, which is a preclinical model for the treatment of Amyotrophic Lateral Sclerosis. In addition, it has a license agreement with Washington State University to offer for sale products covered by certain licensed patents, including dihexa, the chemical compound into which fosgonimeton metabolizes following administration; and collaboration and grant agreement with National Institutes of Health Grant to support ACT-AD Phase 2 clinical trial for fosgonimeton. The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. Athira Pharma, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.
Receive News & Ratings for Immix Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immix Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
